Research dossier
Clinical research on Vitamin D
10 trials reviewed across 8 indications.
Strongest evidence
General health and longevity
Mechanism
Vitamin D is required for calcium homeostasis, immune competence, and bone health. Frank deficiency causes rickets and osteomalacia.
The strongest case for vitamin D is correcting documented deficiency. Beyond that, the two largest mortality trials (D-Health, VITAL) show no all-cause mortality benefit from supplementing replete adults. Test, replete if low, stop chasing higher levels.
Test 25(OH)D if at risk. Repletion to 30 ng/mL is reasonable; chasing higher levels is not supported by trial data.
Trials cited
D-Health — monthly vitamin D and all-cause mortality
Null · RCT
Neale et al., 2022, Lancet Diabetes & Endocrinology (PMID 35026158)n=21315Second mega-trial that converged with VITAL. Over 21,000 Australian older adults on monthly vitamin D3 for nearly six years. No reduction in all-cause mortality, no reduction in cancer mortality, no reduction in cardiovascular mortality.
Generally vitamin D-replete population. Does not rule out benefit in deficient older adults specifically.
VITAL fracture analysis — vitamin D3 and bone fractures
Null · RCT
LeBoff et al., 2022, NEJM (PMID 35939577)n=25871Pre-specified analysis of fracture outcomes inside VITAL. 2,000 IU/day did not reduce total, nonvertebral, or hip fractures in generally healthy adults not selected for low bone density or low vitamin D. Once again, supplementing the replete did nothing.
Did not enroll people with osteoporosis or documented deficiency. The result does not contradict the older-adult, deficient, fall-prone population where benefit is real.
Bone health and fracture prevention
Mechanism
Vitamin D drives intestinal calcium absorption and regulates parathyroid hormone signaling, which together control bone mineralization and remodeling. Without adequate vitamin D, dietary calcium absorption falls and PTH rises, accelerating bone loss.
Strong evidence in older adults at risk of deficiency: 700–1,000 IU/day with calcium meaningfully reduces falls and hip fractures. In already-replete adults the benefit largely disappears, as VITAL's null fracture analysis showed. Mega-dose annual bolus dosing is harmful, not helpful.
Real benefit in older adults with low or borderline 25(OH)D and adequate calcium intake. Largely null in well-fed, replete populations.
Bischoff-Ferrari meta-analysis — vitamin D and falls in older adults
positive · Meta-analysis
Bischoff-Ferrari et al., 2009, BMJ 339:b3692n=2426Pooled 8 trials of vitamin D in older adults. Doses of 700–1,000 IU/day reduced fall risk by roughly 19%. Lower doses showed no benefit. This is one of the strongest pieces of clinical evidence for vitamin D in the older-adult fall-prevention setting.
Effect concentrated at 700–1,000 IU daily; doses below 700 IU showed no fall-prevention benefit.
VITAL fracture analysis — vitamin D3 and bone fractures
Null · RCT
LeBoff et al., 2022, NEJM (PMID 35939577)n=25871Pre-specified analysis of fracture outcomes inside VITAL. 2,000 IU/day did not reduce total, nonvertebral, or hip fractures in generally healthy adults not selected for low bone density or low vitamin D. Once again, supplementing the replete did nothing.
Did not enroll people with osteoporosis or documented deficiency. The result does not contradict the older-adult, deficient, fall-prone population where benefit is real.
Sanders annual bolus — high-dose vitamin D and fractures in older women
negative · RCT
Sanders et al., 2010, JAMA (PMID 20460620)n=2256Older women given a single annual mega-dose of 500,000 IU vitamin D3. Counter-intuitively, the supplemented group had MORE falls and MORE fractures than placebo, especially in the first three months after each yearly dose. The harm signal was real and statistically significant.
Foundational evidence that mega-dose bolus dosing is not just useless but harmful. Daily moderate dosing remains the recommended approach.
Muscle function and fall prevention
Mechanism
Skeletal muscle expresses the vitamin D receptor. Low 25(OH)D is consistently linked to weakness and impaired type II fiber function, particularly in older adults.
Daily 700–1,000 IU vitamin D reduces falls in older adults by roughly 19% in pooled trials. Lower doses don't work; mega-doses can backfire.
Strongest in adults 65+ with baseline insufficiency. Limited evidence in young, replete adults.
Bischoff-Ferrari meta-analysis — vitamin D and falls in older adults
positive · Meta-analysis
Bischoff-Ferrari et al., 2009, BMJ 339:b3692n=2426Pooled 8 trials of vitamin D in older adults. Doses of 700–1,000 IU/day reduced fall risk by roughly 19%. Lower doses showed no benefit. This is one of the strongest pieces of clinical evidence for vitamin D in the older-adult fall-prevention setting.
Effect concentrated at 700–1,000 IU daily; doses below 700 IU showed no fall-prevention benefit.
Respiratory infections
Mechanism
Vitamin D supports cathelicidin and defensin production in airway epithelium and modulates T-cell response. Deficient individuals show impaired innate immunity to respiratory pathogens.
Individual-participant meta-analyses of 46 trials show modest reductions in acute respiratory infections, with the largest effect in starting deficiency below 25 nmol/L. The benefit is real but small in absolute terms — daily dosing only, bolus dosing doesn't work.
Most useful for adults with documented deficiency or insufficiency. Modest if any effect in fully replete adults.
Martineau meta-analysis — vitamin D for respiratory infections
positive · Meta-analysis
Martineau et al., 2017, BMJ (PMID 28202713)n=10933Individual-participant meta-analysis of 25 randomized trials and nearly 11,000 people. Daily or weekly vitamin D supplementation modestly reduced acute respiratory infection risk, with the largest effect in adults with starting 25(OH)D below 25 nmol/L (frank deficiency). Bolus dosing did not work.
Effect size is modest; benefit concentrated in deficient subgroups. Daily or weekly dosing only — bolus was ineffective.
Jolliffe update — vitamin D and respiratory infections
positive · Meta-analysis
Jolliffe et al., 2021, Lancet Diabetes & Endocrinology (PMID 33798465)n=46331Updated individual-participant meta-analysis adding 21 new trials. Modest protective effect against acute respiratory infections persisted. Effect was small in absolute terms — number-needed-to-treat was high — but consistent across populations.
Modest effect size. Daily dosing of moderate amounts (400–1000 IU) was as effective as higher doses.
Fatigue and energy
Mechanism
Severe vitamin D deficiency causes proximal muscle weakness and fatigue, both of which respond to repletion. The benefit is repletion-based, not pharmacological.
Adults with frank deficiency frequently report energy improvement on repletion. There is no controlled-trial evidence that supplementing the replete improves energy in healthy adults.
Worth checking 25(OH)D if persistent fatigue is unexplained — repletion of frank deficiency is reasonable. Doesn't help non-deficient adults.
Cardiovascular disease
Mechanism
Mechanistic data linked vitamin D to endothelial function and renin-angiotensin signaling. The mechanism didn't translate to outcomes.
Both VITAL (n=25,871) and ViDA (n=5,108) randomized large generally-healthy populations to vitamin D and found no reduction in cardiovascular events. The cardiovascular hypothesis didn't survive contact with proper trials.
Routine vitamin D for cardiovascular prevention is not supported by randomized evidence.
VITAL — vitamin D3 for cancer and cardiovascular events
Null · RCT
Manson et al., 2019, NEJM (PMID 30415629)n=25871Largest primary-prevention vitamin D trial ever run. 25,871 generally healthy adults randomized to 2,000 IU/day or placebo for over five years. No reduction in invasive cancer incidence and no reduction in major cardiovascular events. The headline conclusion: routine vitamin D supplementation does not prevent cancer or heart disease in already-replete adults.
Baseline 25(OH)D in this population was already adequate. The trial answers the everyday question of whether topping up a normal level helps — not whether correcting frank deficiency helps.
ViDA — vitamin D and cardiovascular disease
Null · RCT
Scragg et al., 2017, JAMA Cardiology (PMID 28384800)n=5108Monthly bolus dosing in over 5,000 New Zealand adults. No reduction in cardiovascular disease events vs placebo. Adds to the converging evidence that vitamin D supplementation does not prevent cardiovascular disease.
Used monthly bolus dosing rather than daily, which some researchers argue is metabolically different from daily intake.
Cancer prevention
Mechanism
Vitamin D regulates cell proliferation, differentiation, and apoptosis in vitro. The mechanistic story was always strong; the clinical story is not.
VITAL's cancer-incidence endpoint was null over 5+ years in nearly 26,000 adults. Total cancer mortality was also unchanged in D-Health. Routine vitamin D supplementation does not prevent cancer.
Some sub-analyses suggest possible benefit in normal-BMI adults, but these are exploratory and not confirmed.
VITAL — vitamin D3 for cancer and cardiovascular events
Null · RCT
Manson et al., 2019, NEJM (PMID 30415629)n=25871Largest primary-prevention vitamin D trial ever run. 25,871 generally healthy adults randomized to 2,000 IU/day or placebo for over five years. No reduction in invasive cancer incidence and no reduction in major cardiovascular events. The headline conclusion: routine vitamin D supplementation does not prevent cancer or heart disease in already-replete adults.
Baseline 25(OH)D in this population was already adequate. The trial answers the everyday question of whether topping up a normal level helps — not whether correcting frank deficiency helps.
Type 2 diabetes prevention
Mechanism
Observational data linked low vitamin D to insulin resistance and beta-cell dysfunction. The mechanism didn't carry into the trial.
D2d randomized over 2,400 pre-diabetic adults to 4,000 IU/day for 2.5 years. No reduction in progression to type 2 diabetes. The directional signal in low-D subgroups was not statistically significant in the primary analysis.
Routine vitamin D for diabetes prevention is not supported. Repletion in deficient diabetics is reasonable on general grounds.
D2d — vitamin D for type 2 diabetes prevention
Null · RCT
Pittas et al., 2019, NEJM (PMID 31173679)n=2423Pre-diabetic adults randomized to 4,000 IU/day or placebo. No statistically significant reduction in progression to type 2 diabetes. Closes the prevention argument for the dose-and-population most enthusiasts cited.
There was a directional but non-significant trend; subgroup analyses in low-baseline-D participants showed possible benefit but the trial was not designed to confirm subgroup claims.
3 forms of Vitamin D compared
Vitamin D3 (cholecalciferol)
Preferred — raises serum 25(OH)D more efficiently than D2
Best forRoutine supplementation, repletion of insufficiencyThe form your skin makes from sunlight. Used in nearly every modern major trial including VITAL, D-Health, and ViDA. Default choice.
Vitamin D2 (ergocalciferol)
Less efficient than D3 at raising 25(OH)D, especially with intermittent dosing
Best forPlant-based supplementation, prescription high-dose 50,000 IU capsulesDerived from yeast or fungi. Functionally weaker than D3 unit-for-unit. Used in older fortification programs and prescription-strength repletion.
Calcifediol (25-hydroxyvitamin D3)
Bypasses the liver hydroxylation step — raises 25(OH)D faster than D3
Best forPrescription, rapid repletion in malabsorption or liver diseaseThe form measured in standard 25(OH)D blood tests. Used in the small Cordoba COVID-19 pilot. Not a routine over-the-counter supplement in most markets.
Are you deficient? Symptoms, risk groups, lab tests
Roughly 25–35% of US adults have 25(OH)D below 20 ng/mL (50 nmol/L), the threshold for frank deficiency. Insufficiency below 30 ng/mL is even more common, especially in winter, in higher latitudes, in darker-skinned populations, and in older adults.
Common symptoms
- Bone pain or aching, particularly in the lower back, hips, and ribs
- Proximal muscle weakness — difficulty climbing stairs or rising from a chair
- Frequent falls in older adults
- Fatigue and general low energy
- Increased risk of stress fractures
- Persistent low mood (correlation, not established causation)
- Slow wound healing
- Increased frequency of respiratory infections
- In children: rickets — bowed legs, delayed growth, skeletal deformities
- In adults: osteomalacia — soft, painful bones
Who is at risk
Older adults, especially housebound or in care
Skin synthesis of vitamin D from sunlight drops sharply with age, intake is often low, and sun exposure is reduced. Combined with age-related kidney changes, hypovitaminosis D is the norm rather than the exception.
Darker-skinned populations at higher latitudes
Increased melanin reduces UVB-driven cutaneous vitamin D synthesis. Combined with limited winter UVB at higher latitudes, deficiency rates can exceed 50%.
Adults with limited sun exposure
Office-bound work, full-coverage clothing, consistent sunscreen use, and northern winters all suppress endogenous vitamin D production.
People with obesity
Vitamin D is fat-soluble and gets sequestered in adipose tissue, lowering circulating 25(OH)D. Higher doses are typically needed to reach the same blood level.
Adults with malabsorption disorders
Crohn's, celiac, cystic fibrosis, and bariatric surgery all impair fat-soluble vitamin absorption.
Adults with chronic kidney or liver disease
The kidney converts 25(OH)D to active 1,25(OH)2D, and the liver performs the first hydroxylation step. Either organ failing impairs vitamin D activation.
e.g. phenytoin, carbamazepine, phenobarbital, rifampin, glucocorticoids
Long-term users of certain medications
Several anticonvulsants and glucocorticoids accelerate vitamin D catabolism via cytochrome P450 induction.
Exclusively breastfed infants without supplementation
Breast milk is low in vitamin D. The American Academy of Pediatrics recommends 400 IU/day for all breastfed infants from the first days of life.
Lab markers
Serum 25-hydroxyvitamin D — 25(OH)D
The standard test for vitamin D status. Reflects both diet/supplement intake and skin synthesis. Active 1,25(OH)2D is poorly correlated with status and should not be used as a screening test.
Better:1,25-dihydroxyvitamin D (only for specialist evaluation)
- Frank deficiency
- <20 ng/mL (<50 nmol/L)
- Insufficiency
- 20–29 ng/mL (50–74 nmol/L)
- Sufficiency
- 30–50 ng/mL (75–125 nmol/L)
- High — no added benefit, possible harm above this
- >50 ng/mL (>125 nmol/L)
Side effects and drug interactions
Side effects
Hypercalcemia
Uncommon · Sustained intake above 10,000 IU/day or serum 25(OH)D above 100 ng/mL
Excess vitamin D drives calcium absorption beyond what the body needs, raising serum calcium. Causes nausea, constipation, kidney stones, and confusion at higher levels.
Kidney stones
Uncommon · Especially when combined with calcium supplementation above 1,000 mg/day
Higher calcium absorption increases urinary calcium excretion, raising the risk of calcium oxalate stones in susceptible individuals.
Increased falls and fractures with mega-bolus dosing
Uncommon · Single doses of 300,000 IU or higher
Annual 500,000 IU bolus dosing in older women paradoxically increased falls and fractures, especially in the first three months after each dose (Sanders 2010).
Nausea, vomiting, weak appetite
Uncommon
Early symptoms of vitamin D toxicity, typically secondary to hypercalcemia.
Cardiac arrhythmias
Rare
Severe vitamin D toxicity with hypercalcemia can disturb cardiac conduction.
Acute kidney injury
Severe
Sustained hypercalcemia from vitamin D toxicity can damage kidney function.
Drug interactions
Additive effect
thiazide diuretics (hydrochlorothiazide, chlorthalidone)Thiazide diuretics reduce urinary calcium excretion. Combined with vitamin D-driven calcium absorption, the additive effect can produce hypercalcemia.
Reasonable to use both, but consider periodic calcium monitoring, especially at vitamin D doses above 2,000 IU/day.
Combined-effect risk
calcium supplementsVitamin D enhances intestinal calcium absorption. High-dose calcium combined with high-dose vitamin D raises stone-forming risk.
Match calcium intake to actual dietary gaps rather than reflexively stacking. The Women's Health Initiative showed combined calcium + vitamin D modestly increased stones.
Reduces nutrient status
phenytoincarbamazepinephenobarbitalrifampinglucocorticoidsCytochrome P450 induction accelerates vitamin D catabolism, lowering 25(OH)D.
Long-term users of these medications often need higher vitamin D intake to maintain status. Test 25(OH)D periodically.
Reduces nutrient status
orlistatbile acid sequestrants (cholestyramine, colestipol)mineral oilThese agents impair fat-soluble vitamin absorption, reducing vitamin D uptake from supplements and food.
Separate vitamin D dosing from these drugs by at least 2 hours and consider a higher dose.
Other critical caveats
- Avoid mega-dose annual bolus regimens. The 500,000 IU yearly dose in Sanders 2010 increased falls and fractures, not reduced them. Daily moderate dosing (1,000–2,000 IU) is the supported approach.
- The Institute of Medicine upper limit for adults is 4,000 IU/day. Sustained intake above this without 25(OH)D monitoring risks hypercalcemia and kidney stones.
- Combining vitamin D with high-dose calcium without monitoring increases stone-forming risk. Match calcium intake to actual dietary gaps; do not stack reflexively.
Frequently asked
How much vitamin D should I take?
For most adults: 1,000–2,000 IU/day of vitamin D3 is the well-supported range. The IOM upper limit is 4,000 IU/day. If you are over 65 and at fall risk, the 700–1,000 IU/day range is the dose that reduced falls in pooled trials. Above 4,000 IU/day, get your 25(OH)D tested rather than guess.Should I take vitamin D2 or D3?
D3 (cholecalciferol). It raises 25(OH)D more efficiently than D2 (ergocalciferol), particularly with intermittent dosing. Every modern major trial — VITAL, D-Health, ViDA — used D3. D2 is fine if you need a plant-based source, but it is the weaker form unit-for-unit.Will vitamin D prevent cancer or heart disease?
No, based on the largest trials ever run. VITAL (n=25,871) and D-Health (n=21,315) randomized adults to vitamin D and found no reduction in cancer or cardiovascular events. The mechanistic story was strong; the clinical story is not. Vitamin D is for bone health and correcting deficiency, not for cancer or cardiovascular prevention.Should I get tested before supplementing?
If you can, yes. A 25(OH)D blood test costs little and tells you whether you actually need supplementation. Below 20 ng/mL is frank deficiency and worth treating. Above 30 ng/mL, supplementing further has no proven benefit. Testing is more useful than guessing.Can I take too much vitamin D?
Yes. Sustained intake above 10,000 IU/day or 25(OH)D above 100 ng/mL can drive hypercalcemia, kidney stones, and at extremes, kidney injury and cardiac arrhythmias. The Sanders 2010 trial of annual 500,000 IU bolus dosing actually increased falls and fractures. More is not better.
References
- 01NIH Office of Dietary Supplements — Vitamin D Health Professional Fact Sheet
- 02StatPearls — Vitamin D Deficiency (NCBI Bookshelf)
- 03StatPearls — Vitamin D Toxicity (NCBI Bookshelf)
Last reviewed2026-05-07